Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 780 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene expression study Clear all
Completed No phase listed Observational

Study of Tumor Samples From Patients With Lung Cancer

NCT00900328
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated No phase listed Observational Results available

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

NCT01182298
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)

NCT07579442
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Narrative Medicine (NM) Workshop Series
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1 Interventional

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

NCT03324373
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy
Drug · Procedure
Lead sponsor
Yousef Zakharia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

NCT04699630
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
U3-1402
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 2 Interventional

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

NCT07673341
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Not applicable Interventional

Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy

NCT05283200
View directory record Official record
Conditions
Lifestyle
Interventions
Yoga, Cognitive Behavioral Therapy, Music
Behavioral
Lead sponsor
Imad Najm MD
Other
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional

Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma

NCT05989230
View directory record Official record
Conditions
Orthopaedic Trauma, Chronic Pain, Musculoskeletal Injury
Interventions
Emotional Awareness and Expression Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated No phase listed Observational

Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

NCT04267016
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
TruGraf Testing - Peripheral blood gene expression profiling
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

NCT01343043
View directory record Official record
Conditions
Neoplasms
Interventions
NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00723203
View directory record Official record
Conditions
Leukemia
Interventions
panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117
View directory record Official record
Conditions
HCC
Interventions
GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
Biological · Drug · Device
Lead sponsor
Geneos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 1 Interventional

Multimodal Imaging Outcome Measures for ALS (Image ALS)

NCT04490096
View directory record Official record
Conditions
ALS
Interventions
[11C]-PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

NCT02581631
View directory record Official record
Conditions
Non-Hodgkin's Disease
Interventions
Nivolumab, Brentuximab Vedotin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls

NCT01379716
View directory record Official record
Conditions
Postherpetic Neuralgia, Healthy Age/Gender Matched Volunteers
Interventions
skin biopsy
Other
Lead sponsor
Albany Medical College
Other
Eligibility
50 Years to 95 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

NCT01231399
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, everolimus, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting No phase listed Observational

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

NCT07050433
View directory record Official record
Conditions
Prostate Cancer
Interventions
CXCR2 as a biomarker
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Withdrawn Phase 1 Interventional

Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

NCT05340426
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
UKidney
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated No phase listed Observational

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504
View directory record Official record
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

NCT04976803
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
Determination of ATM alteration status.
Other
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease

NCT01194362
View directory record Official record
Conditions
Aortic Valve Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 8:38 PM EDT